2. GPCR/G Protein TGF-beta/Smad
  3. Endothelin Receptor TGF-β Receptor
  4. Sitaxsentan

Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Sitaxsentan

Sitaxsentan 화학구조

CAS No. : 184036-34-8

사이즈 가격 재고 수량
5 mg 견적 받기 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
10 mg 견적 받기 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
25 mg 견적 받기 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
50 mg 견적 받기 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
100 mg 견적 받기 3 - 5 weeks 2 - 4 weeks 4 - 6 weeks 2 - 4 weeks
200 mg   견적 받기  
500 mg   견적 받기  
Synthetic products have potential research and development risk.

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 2 publication(s) in Google Scholar

Other Forms of Sitaxsentan:

Sitaxsentan Related Antibodies

Top Publications Citing Use of Products

View All Endothelin Receptor Isoform Specific Products:

View All Isoforms
ETA ETB

View All TGF-β Receptor Isoform Specific Products:

View All Isoforms
ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B BMP

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Sitaxsentan (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally active endothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan is metabolized by CYP2C9 and CYP3A4, normalizes shunt-induced endothelial abnormalities, restores BMPR signaling, and suppresses pulmonary vascular remodeling and hemodynamic deterioration. Sitaxsentan can be applied in the research of pulmonary arterial hypertension and portopulmonary hypertension[1][2][3][4][5].

IC50 & Target[4]

ETA

1.4 nM (IC50)

ETA

0.43 nM (Ki)

ETB

9800 nM (IC50)

In Vitro

Sitaxsentan (100 μM, 10 min) significantly inhibits taurocholate cotransporter (NTCP) and organic anion transporter (OATP) transportation in sandwich-cultured human hepatocytes[3].
Sitaxsentan (10 min) has a high efficiency of liver cell uptake and almost no bile excretion[3].
Sitaxsentan has moderate hepatobiliary transporters bile salt export pump (BSEP) inhibition (IC50 = 25 μM) in sandwich-cultured human hepatocytes[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sitaxsentan Related Antibodies
In Vivo

Sitaxsentan (1.5 mg/kg, p.o., three times a day for 3 months) effectively prevents PAH caused by shunt induction, and the combined medication with Sildenafil (HY-15025) has a better effect in piglets[1].
Sitaxsentan (5 mg/kg, i.v., single dose) completely blocks the activation of ETA receptors in the acute hypoxia model of rats[2].
Sitaxsentan (15-30 mg/kg, p.o., once daily for 2-4 weeks) significantly improves PAH and vascular remodeling caused by chronic hypoxia, but has limited effect on the already formed right ventricular hypertrophy in rat chronic hypoxia model[2].
Sitaxsentan (10-50 mg/kg, p.o., once daily for 3 weeks) dose-dependently improves Monocrotaline(HY-N0750)-induced pulmonary hypertension in rats[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Shunt-induced PAH model established in piglets (18 days old, 5.3 kg)[1]
Dosage: 1.5 mg/kg or 1.5 mg/kg combined with 0.75 mg/kg Sildenafil
Administration: Oral administration (p.o.) with food, three times a day for 3 months
Result: Combined treatment completely restored the normal state.
Partially inhibited the thickening of blood vessels with single-drug and the combined therapy almost completely prevented it.
Partially restored the expression of BMPR-1A and BMPR-2.
Maintained normal right ventricle-aorta coupling.
Animal Model: Acute hypoxia induced PHA model established in male Sprague-Dawley rats[2]
Dosage: 5 mg/kg
Administration: Intravenous injection (i.v.), 10 minutes before or 50 minutes after the onset of hypoxia
Result: Completely blocked the increase in pressure in prevention group.
Rapidly reversed the elevated MPAP after administration of the drug (reaching normal levels within approximately 30 minutes) in treatment group.
Animal Model: Chronic hypoxia induced PHA model established in male Sprague-Dawley rats[2]
Dosage: 15 mg/kg in prevention group and 15 mg/kg and 30 mg/kg in treatment group
Administration: Oral administration (p.o.) with water, once daily, 48 hours before hypoxia and lasting for 2 weeks or after 2 weeks of hypoxia and lasted for 4 weeks
Result: Decreased The MPAP in the prevention group by 35%, and in the treatment group decreased by 38%.
Reduced the ratio of RV/(LV + S) to some extent.
Improved pulmonary vascular remodeling in both groups.
Animal Model: Monocrotaline induced PHA model established in male Sprague-Dawley rats[2]
Dosage: 10 and 50 mg/kg
Administration: Oral administration (p.o.) with water, once daily for 3 weeks
Result: Improved hemodynamic conditions.
Almost completely prevented pulmonary vascular remodeling at high dose (50mg/kg).
Clinical Trial
분자량

454.90

화학식

C18H15ClN2O6S2
CAS No.
SMILES

O=S(C1=C(C(CC2=CC3=C(C=C2C)OCO3)=O)SC=C1)(NC4=C(C(C)=NO4)Cl)=O
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sitaxsentan Related Classifications

  • 몰농도 계산기

  • 농도 희석 계산기

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sitaxsentan184036-34-8IPI 1040 TBC-11251IPI1040IPI-1040TBC11251TBC 11251TBC-11251Endothelin ReceptorTGF-β ReceptorTransforming growth factor beta receptorsportopulmonary hypertensionbone morphogenetic protein receptor-1Apulmonary arterial hypertensionBMPR-2CYP3A4CYP2C9endothelin A receptorendothelin B receptorsendothelin-1hepatocytesInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Sitaxsentan
Cat. No.:
HY-76520
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.